JPWO2020084480A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020084480A5 JPWO2020084480A5 JP2021521995A JP2021521995A JPWO2020084480A5 JP WO2020084480 A5 JPWO2020084480 A5 JP WO2020084480A5 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP WO2020084480 A5 JPWO2020084480 A5 JP WO2020084480A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- fluorines
- salt according
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000001153 fluoro group Chemical group F* 0.000 claims description 26
- 235000019000 fluorine Nutrition 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 8
- 208000037357 HIV infectious disease Diseases 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 108010002459 HIV Integrase Proteins 0.000 claims description 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims description 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750395P | 2018-10-25 | 2018-10-25 | |
| US62/750,395 | 2018-10-25 | ||
| PCT/IB2019/059004 WO2020084480A1 (en) | 2018-10-25 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022505597A JP2022505597A (ja) | 2022-01-14 |
| JPWO2020084480A5 true JPWO2020084480A5 (https=) | 2022-10-11 |
| JP2022505597A5 JP2022505597A5 (https=) | 2022-10-11 |
| JP7500555B2 JP7500555B2 (ja) | 2024-06-17 |
Family
ID=68344929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521995A Active JP7500555B2 (ja) | 2018-10-25 | 2019-10-22 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210393633A1 (https=) |
| EP (1) | EP3870575B1 (https=) |
| JP (1) | JP7500555B2 (https=) |
| ES (1) | ES2942998T3 (https=) |
| PT (1) | PT3870575T (https=) |
| WO (1) | WO2020084480A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019198024A1 (en) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| US20210395262A1 (en) * | 2018-10-24 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| EP3962603A1 (en) * | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| KR20220066922A (ko) * | 2019-09-20 | 2022-05-24 | 아이디어야 바이오사이언시스 인코포레이티드 | Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| PT3186239T (pt) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| US20210379071A1 (en) * | 2018-11-05 | 2021-12-09 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
-
2019
- 2019-10-22 US US17/284,855 patent/US20210393633A1/en not_active Abandoned
- 2019-10-22 WO PCT/IB2019/059004 patent/WO2020084480A1/en not_active Ceased
- 2019-10-22 PT PT197946791T patent/PT3870575T/pt unknown
- 2019-10-22 JP JP2021521995A patent/JP7500555B2/ja active Active
- 2019-10-22 EP EP19794679.1A patent/EP3870575B1/en active Active
- 2019-10-22 ES ES19794679T patent/ES2942998T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020084480A5 (https=) | ||
| DK169333B1 (da) | Fremgangsmåde til fremstilling af optisk aktive S(-)-carbazolderivater, nye S(-)-carbazolderivater, samt lægemidler, der indeholder disse forbindelser | |
| JP2003503385A5 (https=) | ||
| JP2022500425A5 (https=) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| JP2004514663A5 (https=) | ||
| JP2006528700A5 (https=) | ||
| JP2021102643A5 (https=) | ||
| JP2024173998A5 (https=) | ||
| RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
| JP2004517843A5 (https=) | ||
| JP2007507494A5 (https=) | ||
| JPWO2020084492A5 (https=) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| JP2004525178A5 (https=) | ||
| JP2005516898A5 (https=) | ||
| JP2006510658A5 (https=) | ||
| JPWO2020089778A5 (https=) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| JPWO2020084491A5 (https=) | ||
| JP2008521934A5 (https=) | ||
| JPWO2020053811A5 (https=) | ||
| RU2007125130A (ru) | Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1 | |
| JPWO2020058844A5 (https=) |